Phortress
Based on 1 Customer Validation
Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1.
For research use only. We do not sell to patients.
- Purity : 98.19%
- CAS No.: 328087-38-3
- Formula: C20H25Cl2FN4OS
- Molecular Weight:459.41
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-19317
ITEAryl Hydrocarbon Receptor Agonist -
HY-124421
5F-203AhR Agonist -
HY-103223R
Phortress (Standard)Reference Standard -
HY-104026
L-KynurenineAryl Hydrocarbon Receptor Agonist -
HY-111278
PyocyaninSecondary Metabolite -
HY-12684
CH-223191AhR Antagonist -
HY-112554
PDM11Resveratrol Derivative -
HY-104026R
L-Kynurenine (Standard)Aryl Hydrocarbon Receptor Agonist -
HY-15001
Stemregenin 1AhR Antagonist -
HY-124421R
5F-203 (Standard)Reference Standard -
HY-103221
MeBIOAhR Agonist -
HY-103220
6,2',4'-TrimethoxyflavoneAHR Antagonist
Biological Activity
Description
IC50 & Target
|
CYP1 |
Chemical Information
-
CAS No. 328087-38-3
-
Appearance Solid
-
Molecular Weight 459.41
-
Formula C20H25Cl2FN4OS
-
Color Light yellow to yellow
-
SMILES
O=C(NC1=CC=C(C2=NC3=CC(F)=CC=C3S2)C=C1C)[C@@H](N)CCCCN.[H]Cl.[H]Cl
-
Synonyms
NSC 710305
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (272.09 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bradshaw TD, et al. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer. 2002 Apr 22;86(8):1348-54. [Content Brief]
[2]. Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem. 2004 Apr;11(8):1009-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1767 mL | 10.8835 mL | 21.7670 mL | 54.4176 mL |
| 5 mM | 0.4353 mL | 2.1767 mL | 4.3534 mL | 10.8835 mL | |
| 10 mM | 0.2177 mL | 1.0884 mL | 2.1767 mL | 5.4418 mL | |
| 15 mM | 0.1451 mL | 0.7256 mL | 1.4511 mL | 3.6278 mL | |
| 20 mM | 0.1088 mL | 0.5442 mL | 1.0884 mL | 2.7209 mL | |
| 25 mM | 0.0871 mL | 0.4353 mL | 0.8707 mL | 2.1767 mL | |
| 30 mM | 0.0726 mL | 0.3628 mL | 0.7256 mL | 1.8139 mL | |
| 40 mM | 0.0544 mL | 0.2721 mL | 0.5442 mL | 1.3604 mL | |
| 50 mM | 0.0435 mL | 0.2177 mL | 0.4353 mL | 1.0884 mL | |
| 60 mM | 0.0363 mL | 0.1814 mL | 0.3628 mL | 0.9070 mL | |
| 80 mM | 0.0272 mL | 0.1360 mL | 0.2721 mL | 0.6802 mL | |
| 100 mM | 0.0218 mL | 0.1088 mL | 0.2177 mL | 0.5442 mL |
Phortress Related Classifications
HY-103223 Related Classifications
Powered by Bioz